Global Link
English 繁體中文
Company Overview Board of Directors Leadership Scientific Advisory Board

Ben Chien, Ph.D.

Chairman & CEO

Max Chan, MBA

Chief Financial Officer

Yisheng Lee, M.D., Ph.D., MBA

Chief Medical Officer

Yuhua Li, Ph.D.

Co-founder, Chief Technology Officer

Wenjin Yang, Ph.D.

Chief Scientific Officer

Mathieu Boudreau, Ph.D.

Chief Business Officer & Chief Operating Officer

Brian J. Groch

Chief Commercial Officer

Bassem Elmankabadi, M.D.

Senior Vice President of Clinical Development

Bill Miller, Ph.D.

Vice President, Regulatory Affairs

John Sheehan, Ph.D.

Vice President of CMC

Scott Johnson

Executive Director and Head of QA

We use cookies to provide the services and features offered on our website, and to improve our user experience.
By using this website, you consent to the use of cookies and agree to our Privacy policy.

Accept

Ben Chien, Ph.D.

Chairman & CEO

Ben is Founder, Chairman & CEO of Foresee Pharmaceuticals. Foresee was initially a research division of QPS Holdings, LLC and spun-off in 2011. QPS was founded in 1995 to provide high quality bioanalytical LC-MS/MS contract services. Since then, QPS has posted impressive growth every year and has grown from a small molecule bioanalysis shop of three people to more than 1,200+ employees in the United States, Europe, India and Asia. Over the years, the company has adopted additional services, including Pharmacology, DMPK, Toxicology, Translational Medicine, Early Phase Clinical Research and Phase II – IV Clinical Research.

Ben obtained his Ph.D. in analytical chemistry (mass spectrometry) from the University of Michigan at Ann Arbor with Prof. David M. Lubman. Ben is the co-inventor of a novel Ion Trap/Time-of-Flight Mass Spectrometer. The publication of this work was selected as “Best Student Paper of 1994”, awarded by International Journal of Mass Spectrometry and Ion Physics. Ben began his pharmaceutical career at DuPont Merck Pharmaceutical Co. in the Drug Metabolism and Pharmacokinetics Section, where he built the LC/MS/MS group dedicated to supporting drug discovery, preclinical and clinical studies. In 1996, Ben received the Summit Award, the highest level of achievement at DuPont Merck for his dedicated contribution to the development of Efavirenz, an anti-viral drug approved by the FDA for the treatment of HIV disease.

Max Chan, MBA

Chief Financial Officer

Max Chan is a seasoned Chief Financial Officer with capital/fund raising, IPO planning and execution experience; in addition, Max is well connected with investor community. The expertise, knowledge and experience that Max brings to Foresee will further strengthen our capacity in the commercial planning strategies and executions. After working at China Development Industrial Bank (1992~2000) and Intel Capital (2000~2004), Max joined Himax (Nasdaq: HIMX) in 2004 and served as their CFO until 2010, when he switched to the biopharmaceutical sector and served as CFO in Taigen Biopharmaceutical, JHL Biotech and OBI Pharma from 2010~2019; Max had played an integral role in numerous strategic initiatives, including IPO, funding raising, licensing, and M&A. 


Max Chan received his B.S. degree in Civil Engineering and MBA degree in Finance from the National Taiwan University and received another M.S. degree in Business Administration from the University of Illinois at Urbana Champaign, USA.

Yisheng Lee, M.D., Ph.D., MBA

Chief Medical Officer

Dr. Yisheng Lee brings extensive leadership experience in patient care, new drug clinical trial execution and medical research that will help build Foresee's competitive advantage in the implementation of clinical development strategies and trial designs. Dr. Lee has practiced pediatric hematology/oncology and held multiple academic appointments (teaching and research) at Harvard, Duke, Stanford, and UCSF Medical Schools over the past 30 years. 


Dr. Lee received a medical doctor degree as an honor graduate from National Taiwan University, a Ph. D. in Tumor Immunology/Pathology from Duke University, and an MBA from UC Irvine. Dr. Lee has first-hand patient caring insights and solid academic achievements in pathology, neurology, pediatrics, hematology, and oncology.

Yuhua Li, Ph.D.

Co-founder, Chief Technology Officer

Dr. Li is the co-founder and Chief Technology Officer (CTO) of Foresee Pharmaceuticals Co., Ltd. He brings extensive experience to his role, including strategic business planning, R&D budget and operation, intellectual property (IP) portfolio creation and management, pharmaceutical product development, and interacting with regulatory authorities for new drug approvals. Dr. Li has a proven track record of successful pharmaceutical product development from concept to bench to bedside. He has led the R&D efforts for several promising drug development candidates, including the lead product, Camcevi 42 mg, which achieved approval in the US, Europe, and other countries. Dr. Li also excels in fostering collaboration and building partnerships with CROs/CDMOs, pharmaceutical companies, and academic institutions. Prior to Foresee, Dr. Li held key positions in pharmaceutical development, including Director of Formulation R&D at QPS, LLC, Principal Scientist at FeRx Incorporated, and Senior Scientist at GeneMedicine Inc. 


Dr. Li received postdoctoral training from both the University of North Carolina, Chapel Hill, and GlaxoWellcome, Inc., NC. He holds a Ph.D. in Chemistry from Clemson University, SC.

Wenjin Yang, Ph.D.

Chief Scientific Officer

Dr. Yang has over three decades of experience in drug discovery and preclinical development of small molecules and antibody-drug-conjugates in antiviral, anti-inflammatory, neuroscience, metabolic and oncology therapeutic indications. 


Prior to joining Foresee, Dr. Yang was Co-founder and VP of Research at Aldea Pharmaceuticals, where he led the efforts of raising series-A financing (US $11 MM), establishing the research team, setting up the company infrastructure and facility, and advancing the company’s lead program into clinical development. He also contributed to Aldea’s series-B financing (US $24 MM). He previously served as Vice President of Chemistry at Eiger BioPharmaceuticals, where he oversaw research and manufacturing functions. He also served as Director and Head of Medicinal Chemistry at Sunesis Pharmaceuticals, where he was responsible for scientific team management and multiple medicinal chemistry programs, including new technology development, hit identification, and lead optimization to development candidate selection. Before joining Sunesis, Dr. Yang was a Research Scientist at Gilead Sciences, and a postdoctoral research associate at The Scripps Research Institute. Dr. Yang has authored 26 peer-reviewed manuscripts and is an inventor of 28 U.S. issued patents and several additional pending patents. 


Dr. Yang received his B.S. in Chemistry from the Chinese Culture University, and his M.S. and Ph.D. in Organic Chemistry from the University of California, Riverside.

Mathieu Boudreau, Ph.D.

Chief Business Officer & Chief Operating Officer

Dr. Boudreau brings extensive leadership experience in biotechnology and specialty pharmaceuticals companies. Most recently he was Vice President, Corporate Development & Licensing and member of the Executive Committee at Telesta Therapeutics, where he led several strategic transactions, including a significant license agreement for its Phase 3 uro-oncology program with global specialty pharmaceutical company, Ipsen. Dr. Boudreau has amassed broad corporate business development experience that covers the entire transaction lifecycle. He has successfully led and played key roles in both early and late stage/commercial product in-licensing/out-licensing, mergers and acquisitions, corporate strategy, venture creation and operations. Prior to Telesta, Dr. Boudreau was Director, Search & Evaluation - Business Development at Pendopharm, Director, Business Development & Strategic Planning at Pharmascience Inc., and Director, Business Development at Aegera Therapeutics Inc., which was acquired by Pharmascience Inc. in 2011. Dr. Boudreau started his career in business development as co-founder of a diagnostics company. 


Dr. Boudreau holds a Ph.D. in Neuroscience from McGill University and a B.Sc. in Biochemistry from the University of Montreal.

Brian J. Groch

Chief Commercial Officer

Brian is a seasoned healthcare executive with over 30 years of expertise in the pharmaceutical industry. Throughout his career, he has held multiple C-suite leadership roles, serving as CEO at Remi Therapeutics, President and Chief Commercial Officer (CCO) at Shield Therapeutics, and CCO at Veru Inc. He has a proven track record in leading global market access strategies, driving corporate growth, and overseeing commercial execution. His expertise spans building launch infrastructures and driving the market adoption of innovative treatments across multiple disease areas.


Prior to his executive roles, he served as Director of Health Policy and Regional Sales at Novartis, and spent over 13 years at Merck managing large-scale commercial programs.


He holds an MBA in Business Administration and Marketing from Central Michigan University.

Bassem Elmankabadi, M.D.

Senior Vice President of Clinical Development

Bassem is a board-certified surgeon with over 18 years of diverse experience in clinical practice and the pharmaceutical industry, including Amgen, FibroGen, and Blade Therapeutics. Bassem brings a unique blend of medical expertise and leadership to the field. Throughout his career, he has successfully navigated the intersection of medicine and research, holding pivotal roles that span clinical development, regulatory interactions, and strategic decision-making. At Amgen, Bassem orchestrated the clinical development of PARSABIV and IMLYGIC programs, leading to their global approvals. He has also played a pivotal role in advancing several BiTE Immune-Oncology programs, targeting solid tumors across various phases of development. He had many years of experience leading multiple health agencies in face-to-face interactions and negotiations, resulting in an agreement on four Clinical Development Plans for Phase 2 and 3 clinical studies across several indications of Cudetaxestat (ATX inhibitor) and Pamrevlumab (mAB). 


Bassem's earlier roles have further enriched his journey. He worked as an active surgeon at UCLA, immersing himself in the clinical intricacies of surgery. Additionally, his tenure as a Clinical Instructor and Medical Director for the KRAS oncogene program allowed him to delve into the complexities of targeted therapies for refractory colorectal cancer. Bassem's educational foundation is solidified by rigorous training, including a comprehensive general surgery program at the esteemed Brooklyn Hospital Center and an Internship at SUNY Downstate Medical Center in Brooklyn, New York. 


In a pivotal phase of Bassem’s career, he spent over 5 years collaborating with a Contract Research Organization (CRO), contributing to Phase 2/3 studies in retinal diseases.

Bill Miller, Ph.D.

Vice President, Regulatory Affairs

Dr. Bill Miller is the Vice President of Regulatory Affairs at Foresee Pharmaceuticals. Dr. Miller brings a broad range of experience in regulatory strategy, health authority interactions, and program leadership. Prior to joining Foresee Pharmaceuticals, Dr. Miller worked as a consultant for numerous pharmaceutical and biotech companies for their IND/NDA/BLA filings (US) and as their global regulatory lead for health authority applications for small molecules, biologics and biosimilars. Dr. Miller also was the global regulatory lead for several of CSL Behring’s approved immunodeficiency products, and served as the US regulatory lead for Teva Pharmaceuticals. 


Dr. Miller received his B.S. in Physics from Bloomsburg University of PA and Ph.D. in Bioengineering from University of Pennsylvania.

John Sheehan, Ph.D.

Vice President of CMC

At Foresee, John leads CMC development for multiple small-molecule NCEs and oversees global commercial and clinical supplies. He has been instrumental in launching complex drug/device combination products and expanding global manufacturing capacity. Previously, John held senior roles at Merck, Novartis, and Bristol-Myers Squibb, where he contributed to the successful development, transfer, and launch of oral solids, injectables, implants, transdermals, and ophthalmic products. Recognized for resolving complex formulation and process challenges, he has authored regulatory submissions supporting NDAs, and post-approval changes. With proven technical expertise and strategic leadership, he continues to drive Foresee’s global development and supply strategies. John holds a Ph.D. in Chemical Engineering and a B.S. in Physics from the University of Minnesota.

Scott Johnson

Executive Director and Head of QA

Scott is a results-oriented quality and compliance professional who offers expertise in international GMPs and GxP surveillance across biologics and sterile processing. He has led quality operations for Pharnext and Oyster Point Pharmaceuticals, overseeing clinical trial manufacturing while implementing robust EQMS and supplier management programs. Also, he has experience establishing a comprehensive GXP oversight system and played a pivotal role in the NDA submission and successful commercial launch of Tyrvaya. His experience includes leading cross-functional teams, managing departmental budgets, and driving process improvements with CMOs to ensure regulatory compliance. He specializes in developing employees' skill sets and ensuring quality excellence across the global supply chain through rigorous auditing and inspection readiness.